BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 23237005)

  • 1. Urethral pain among prostate cancer survivors 1 to 14 years after radiation therapy.
    Pettersson N; Olsson C; Tucker SL; Alsadius D; Wilderäng U; Johansson KA; Steineck G
    Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):e29-37. PubMed ID: 23237005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-reported genitourinary toxicity for long-term prostate cancer survivors treated with radiation therapy.
    Olsson CE; Pettersson N; Alsadius D; Wilderäng U; Tucker SL; Johansson KA; Steineck G
    Br J Cancer; 2013 May; 108(10):1964-70. PubMed ID: 23632483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer.
    Mohammed N; Kestin L; Ghilezan M; Krauss D; Vicini F; Brabbins D; Gustafson G; Ye H; Martinez A
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):204-12. PubMed ID: 21167653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-reported sexual toxicity after radiation therapy in long-term prostate cancer survivors.
    Olsson CE; Alsadius D; Pettersson N; Tucker SL; Wilderäng U; Johansson KA; Steineck G
    Br J Cancer; 2015 Sep; 113(5):802-8. PubMed ID: 26241816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of life up to 10 years after external beam radiotherapy and/or brachytherapy for prostate cancer.
    Freiberger C; Berneking V; Vögeli TA; Kirschner-Hermanns R; Eble MJ; Pinkawa M
    Brachytherapy; 2018; 17(3):517-523. PubMed ID: 29496423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostatourethral-rectal fistula after prostate brachytherapy.
    Theodorescu D; Gillenwater JY; Koutrouvelis PG
    Cancer; 2000 Nov; 89(10):2085-91. PubMed ID: 11066049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-reported gastrointestinal symptoms among long-term survivors after radiation therapy for prostate cancer.
    Alsadius D; Olsson C; Pettersson N; Tucker SL; Wilderäng U; Steineck G
    Radiother Oncol; 2014 Aug; 112(2):237-43. PubMed ID: 25201126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
    Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-volume impact in high-dose-rate Iridium-192 brachytherapy as a boost to external beam radiotherapy for localized prostate cancer--a phase II study.
    Pinkawa M; Fischedick K; Treusacher P; Asadpour B; Gagel B; Piroth MD; Borchers H; Jakse G; Eble MJ
    Radiother Oncol; 2006 Jan; 78(1):41-6. PubMed ID: 16271785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival Outcomes of Dose-Escalated External Beam Radiotherapy versus Combined Brachytherapy for Intermediate and High Risk Prostate Cancer Using the National Cancer Data Base.
    Amini A; Jones B; Jackson MW; Yeh N; Waxweiler TV; Maroni P; Kavanagh BD; Raben D
    J Urol; 2016 May; 195(5):1453-1458. PubMed ID: 26576709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer.
    Burri RJ; Stone NN; Unger P; Stock RG
    Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1338-44. PubMed ID: 20138442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort.
    Wedde TB; Småstuen MC; Brabrand S; Fosså SD; Kaasa S; Tafjord G; Russnes KM; Hellebust TP; Lilleby W
    Radiother Oncol; 2019 Mar; 132():211-217. PubMed ID: 30389241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes of patients with localized and locally advanced prostate cancer undergoing high-dose-rate brachytherapy with external-beam radiotherapy at our institute.
    Makino T; Mizokami A; Namiki M
    Anticancer Res; 2015 Mar; 35(3):1723-8. PubMed ID: 25750334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urethral and bladder dosimetry of total and focal salvage Iodine-125 prostate brachytherapy: Late toxicity and dose constraints.
    Peters M; van der Voort van Zyp J; Hoekstra C; Westendorp H; van de Pol S; Moerland M; Maenhout M; Kattevilder R; van Vulpen M
    Radiother Oncol; 2015 Nov; 117(2):262-9. PubMed ID: 26349590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage external beam radiotherapy for locally recurrent prostate cancer after definitive brachytherapy.
    Rutenberg MS; Meister M; Amin PP; Hussain A; Naslund MJ; Kwok Y
    Brachytherapy; 2016; 15(6):722-729. PubMed ID: 27693225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Prospective Phase 2 Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer After External Beam Radiation Therapy (NRG Oncology/RTOG-0526).
    Crook JM; Zhang P; Pisansky TM; Trabulsi EJ; Amin MB; Bice W; Morton G; Pervez N; Vigneault E; Catton C; Michalski J; Roach M; Beyer D; Jani A; Horwitz E; Donavanik V; Sandler H
    Int J Radiat Oncol Biol Phys; 2019 Feb; 103(2):335-343. PubMed ID: 30312717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of Rotating Shield Brachytherapy for Prostate Cancer Dose Escalation and Urethral Sparing.
    Adams Q; Hopfensperger KM; Kim Y; Wu X; Xu W; Shukla H; McGee J; Caster JM; Flynn RT
    Int J Radiat Oncol Biol Phys; 2018 Dec; 102(5):1543-1550. PubMed ID: 30092333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage of locally recurrent prostate cancer after external beam radiation using reduced-dose brachytherapy with neoadjuvant plus adjuvant androgen deprivation.
    Baumann BC; Baumann JC; Christodouleas JP; Soffen E
    Brachytherapy; 2017; 16(2):291-298. PubMed ID: 28139422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.